Home

Eli Lilly (LLY)

829.60
+7.09 (0.86%)

Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues

The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe.

SummaryNewsPress ReleasesChartHistoricalFAQ
Previous Close822.51
Open821.72
Bid829.52
Ask830.00
Day's Range819.50 - 838.00
52 Week Range711.40 - 972.53
Volume983,029
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & Yield5.200 (0.63%)
1 Month Average Volume3,603,756

News & Press Releases

3 Market-Beating Stocks to Target This Week
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.
Via StockStory · March 19, 2025
Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?
Viking Therapeutic may have a GLP-1 blockbuster on their hands with VK2735 as it produces weight loss at 5X the speed of Novo Nordisk's Wegovy GLP-1 drug.
Via MarketBeat · March 18, 2025
Why Hims & Hers Stock Popped on Mondayfool.com
Morgan Stanley had great news for Hims & Hers stock today, so why didn't it upgrade the stock?
Via The Motley Fool · March 17, 2025
This Is What Whales Are Betting On Eli Lillybenzinga.com
Via Benzinga · March 17, 2025
Why Eli Lilly Stock Flopped Todayfool.com
Via The Motley Fool · March 10, 2025
3 Unstoppable Stocks You Can Buy Now Without Any Hesitationfool.com
Via The Motley Fool · March 17, 2025
Top 10 High Alpha Stocks For Dividend Investorstalkmarkets.com
Most investors are seeking outperformance when buying stocks. One of the most popular measures of investment outperformance is alpha.
Via Talk Markets · March 14, 2025
Top gainers and losers in the S&P500 index during Friday's after-hours session.chartmill.com
After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable S&P500 performers among the top gainers and losers.
Via Chartmill · March 14, 2025
What's going on in today's after hours sessionchartmill.com
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via Chartmill · March 14, 2025
CVS Weight Management Program Yields 15% Average Weight Loss, 26% Cost Saving Among Participantsbenzinga.com
CVS Weight Management program members achieved 15% average weight loss, with 92% satisfaction and 26% lower GLP-1 medication costs for participating clients.
Via Benzinga · March 14, 2025
Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disordersbenzinga.com
Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss and liver health benefits.
Via Benzinga · March 14, 2025
3 Healthcare Stocks with Exciting Potential
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six months, the industry has pulled back by 11.2%. This drawdown was much worse than the S&P 500’s 1.1% decline.
Via StockStory · March 14, 2025
Visa, Eli Lilly, Blackstone And A Real Estate Stock On CNBC's 'Final Trades'benzinga.com
Via Benzinga · March 14, 2025
Generate Passive Income From This Low-Cost Vanguard ETF That Is Crushing the S&P 500 in 2025fool.com
Via The Motley Fool · March 14, 2025
Billionaire Ken Griffin More Than Doubled His Stake In This Market-Beating Growth Stockfool.com
Via The Motley Fool · March 14, 2025
3 Reasons to Sell ELAN and 1 Stock to Buy Instead
Elanco has gotten torched over the last six months - since September 2024, its stock price has dropped 28.5% to $10.39 per share. This was partly due to its softer quarterly results and might have investors contemplating their next move.
Via StockStory · March 14, 2025
Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at branded pharmaceuticals stocks, starting with Supernus Pharmaceuticals (NASDAQ:SUPN).
Via StockStory · March 14, 2025
Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analystbenzinga.com
H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.
Via Benzinga · March 13, 2025
On Sale Now: 20 Blue Chip Stocks to Buyfool.com
These 20 blue chip companies are the largest traded on U.S. exchanges.
Via The Motley Fool · March 13, 2025
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Droppedfool.com
Ignore the noise in GLP-1 stocks. Find the best value instead.
Via The Motley Fool · March 12, 2025
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billioninvestors.com
The company is looking to test a combination of the drug it acquired from Carmot Therapeutics and a amylin-based drug.
Via Investor's Business Daily · March 12, 2025
Hims & Hers Stock Is Down 50% From Its High, but Is This a Buying Opportunity?fool.com
Shutting down an acquisition caught investor attention, but there's more to the story.
Via The Motley Fool · March 11, 2025
Is Eli Lilly Stock a Buy?fool.com
Via The Motley Fool · March 11, 2025
The Reality of Trump's Tariffsfool.com
Via The Motley Fool · March 10, 2025
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · March 11, 2025